Assorted News (RegMed) - Page 5 - Ventures & Markets - LONGECITY

ImmInst 01 Nov 2012

RegMed Sector: 10 things you should know of â€¦ this morning
Proactive Investors USA & Canada - 1 hour ago

Worth Knowing â€¦ BioTime, Inc. (NYSE MKT: BTX) and its subsidiary OrthoCyte Corporation appointed Francois Binette, PhD, as OrthoCyte's Vice President of Research and Business Development.

View the full article

Quote

ImmInst 01 Nov 2012

Geron (GERN) Q3 Highlights and Achievements
Proactive Investors USA & Canada - 1 hour ago

Not a bad year but, not totally a good year â€¦ Comments re BioTime (NYSE MKT: BTX) from the conference call: I'd <Dr . John Scarlett, CEO> also like to provide a brief update regarding the potential divestiture of the stem cell programs.

View the full article

Quote

ImmInst 02 Nov 2012

Eli Lilly appoints Melissa Barnes as chief ethics and compliance officer
FierceBiotech - 2 hours ago

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and we will feature it here each Friday.

View the full article

Quote

ImmInst 31 Oct 2012

Geron Posts Narrower Loss - Analyst Blog
NASDAQ - Oct 31, 2012

Geron Corporation ( GERN ) posted a net loss of 13 cents per share in the third quarter of 2012, narrower than the Zacks Consensus Estimate of a loss of 14 cents and the year-ago loss of 16 cents.

View the full article

Quote

ImmInst 05 Nov 2012

PropThink: Geron Q3 Earnings Review: Waiting Not for Godot, but for San ...
Reuters - 14 minutes ago

By Ivan Deryugin. When a biotechnology company is around 20 years after its incorporation, common wisdom would suggest that it has become a major player in the biotechnology sector, with at least one blockbuster drug on the market.

View the full article

Quote

ImmInst 05 Nov 2012

PropThink: Geron Q3 Earnings Review: Waiting Not for Godot, but for San ...
Reuters - 3 hours ago

By Ivan Deryugin. When a biotechnology company is around 20 years after its incorporation, common wisdom would suggest that it has become a major player in the biotechnology sector, with at least one blockbuster drug on the market.

View the full article

Quote

ImmInst 01 Nov 2012

Geron (GERN) Q3 Highlights and Achievements
Proactive Investors USA & Canada - Nov 1, 2012

Not a bad year but, not totally a good year â€¦ Comments re BioTime (NYSE MKT: BTX) from the conference call: I'd <Dr . John Scarlett, CEO> also like to provide a brief update regarding the potential divestiture of the stem cell programs.

View the full article

Quote

ImmInst 06 Nov 2012

RegMed sector co-exists in the down market
Proactive Investors USA & Canada - 3 hours ago

End of Day, Cause and Effect â€¦ RegMed stocks pulled back across the board Friday, as weakness trumped a better-than-expected monthly government jobs report amid nervousness ahead of the presidential election next week.

View the full article

Quote

ImmInst 07 Nov 2012

Five Regenerative Medicine Companies Worthy of Portfolio Addition
Equities.com - 56 minutes ago

Five Regenerative Medicine Companies Worthy of Portfolio Addition. Baystreet.ca. Category: Baystreet Newswire. Company: Emerging Growth Corp.

View the full article

Quote

ImmInst 07 Nov 2012

BIOTIME, INC. : BioTime and Subsidiary Cell Cure Neurosciences Ltd ...
4-traders - 2 hours ago

BioTime, Inc. : BioTime and Subsidiary Cell Cure Neurosciences Ltd. Announce Financing. 11/07/2012| 08:50am US/Eastern. BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Cell Cure Neurosciences Ltd.

View the full article

Quote

ImmInst 07 Nov 2012

Five Regenerative Medicine Companies Worthy of Portfolio Addition
Equities.com - Nov 7, 2012

Five Regenerative Medicine Companies Worthy of Portfolio Addition. Baystreet.ca. Category: Baystreet Newswire. Company: Emerging Growth Corp.

View the full article

Quote

ImmInst 09 Nov 2012

Investor Caution: Indentifying the Next Penny Stocks (AMD, ALU, GERN, MTG ...
24/7 Wall St. - 1 hour ago

Some companies are in real trouble. Some are under severe industry pressure, and some are just faltering due to missteps and bad luck.

View the full article

Quote

ImmInst 09 Nov 2012

BioTime Q3 loss widens â€“ Quick Facts
RTT News - 1 hour ago

BioTime Inc. (BTX: Quote) reported that its third-quarter net loss attributable to the company was $5.0 million or $0.10 per share, compared to a net loss of $3.7 million or $0.08 per share for the same period of 2011.

View the full article

Quote

ImmInst 09 Nov 2012

BioTime Announces Third Quarter 2012 Financial Results and Recent Corporate ...
The Herald | HeraldOnline.com - 1 hour ago

ALAMEDA, Calif. - BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results for the third quarter and year-to-date period ended September 30, 2012 ...

View the full article

Quote

ImmInst 09 Nov 2012

RegMed sector, lackluster Friday as markets settle down
Proactive Investors USA & Canada - 2 hours ago

The 6 W's: Who, what, where, when, why and what of it â€¦ The RegMed sector's choppy trading comes as traders digest the sell-off that was seen over the past 2 days, which reflected concerns about the cash positions, development achievements and ...

View the full article

Quote

ImmInst 11 Nov 2012

BRIEF: BioTime invests 3.5m in Cell Cure through share swap
MENAFN.COM - 45 minutes ago

BRIEF: BioTime invests 3.5m in Cell Cure through share swap. Nov 11, 2012 (Menafn - Globes - McClatchy-Tribune Information Services via COMTEX) --Cell Cure Neurosciences Ltd.

View the full article

Quote

ImmInst 09 Nov 2012

BioTime Announces Third Quarter 2012 Financial Results and Recent Corporate ...
The Herald | HeraldOnline.com - Nov 9, 2012

ALAMEDA, Calif. - BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results for the third quarter and year-to-date period ended September 30, 2012 ...

View the full article

Quote

ImmInst 12 Nov 2012

BIOTIME, INC. : Hadasit Bio-Holdings Ltd. Portfolio Company Cell Cure ...
4-traders - 1 hour ago

BioTime, Inc. : Hadasit Bio-Holdings Ltd. Portfolio Company Cell Cure Neurosciences Ltd. Receives Additional Financing From BioTime Inc. 11/12/2012| 09:05am US/Eastern.

BRIEF: BioTime invests 3.5m in Cell Cure through share swap - MENAFN.COM

View the full article

Quote

ImmInst 13 Nov 2012

Largest NYSE Alternext Short Interest Positions as of Oct. 31
Businessweek - 2 hours ago

Skills Gap: No Big Deal, Ifâ€”â‚¬¦ · B-School Startups: Fulfilling a Dream With Ashesi University · One Year With Solar Energy at Home: Mostly Sunny.

View the full article

Quote

ImmInst 12 Nov 2012

Hadasit Bio-Holdings Ltd. Portfolio Company Cell Cure Neurosciences Ltd ...
PR Newswire (press release) - Nov 12, 2012

JERUSALEM, Nov. 12, 2012 /PRNewswire/ -- Hadasit Bio-Holdings Ltd. (OTC: HADSY, TASE: HDST) a publicly traded portfolio of biotech companies, all based on intellectual property developed by the Hadassah University Hospital, Israel's foremost medical ...

View the full article

Quote

ImmInst 13 Nov 2012

Largest NYSE Alternext Short Interest Positions as of Oct. 31
Bloomberg - 20 hours ago

Largest NYSE Alternext Short Interest Positions as of Oct. 31. By Bloomberg News - 2012-11-13T16:24:28Z. The following are the 100 largest short interest positions on the NYSE Alternext as of the Oct. 31 settlement date.

View the full article

Quote

ImmInst 14 Nov 2012

BIOTIME, INC. : BioTime and Subsidiary LifeMap Sciences Announce the ...
4-traders - 2 hours ago

BioTime, Inc. : BioTime and Subsidiary LifeMap Sciences Announce the Launch of LifeMap BioReagents? Portal. 11/14/2012| 09:05am US/Eastern.

BioTime and Subsidiary LifeMap Sciences Announce the Launch of LifeMap ... - MarketWatch (press release)

View the full article

Quote

ImmInst 15 Nov 2012

StreetInsider.com After-Hours Movers 11/15: (SHF) (ARUN) (GPS) Higher ...
StreetInsider.com (subscription) - 37 minutes ago

Schiff Nutrition International, Inc. (NYSE: SHF) 29% HIGHER; Reckitt Benckiser to acquire the company for $42.00 per share in cash valuing Schiff at approximately $1.4 billion.

View the full article

Quote

ImmInst 17 Nov 2012

Geron to sell embryonic stem cell business to BioTime
San Francisco Business Times (blog) - 55 minutes ago

Geron Corp. will sell its shuttered embryonic stem cell assets to BioTime Inc., according to a non-binding letter of intent signed by the companies.

View the full article

Quote

ImmInst 14 Nov 2012

BIOTIME, INC. : BioTime and Subsidiary LifeMap Sciences Announce the ...
4-traders - Nov 14, 2012

BioTime, Inc. (NYSE MKT: BTX) and its subsidiary LifeMap Sciences have announced the launch of LifeMap BioReagents? (http://bioreagents.

View the full article

Quote

ImmInst 16 Nov 2012

Geron-BioTime Sign LOI - Analyst Blog
NASDAQ - Nov 16, 2012

A year after announcing its decision to exit stem cell therapy, Geron Corporation ( GERN ) announced that it has entered into a non-binding letter of intent (LOI) with BioTime, Inc. ( BTX ) and BioTime`s subsidiary, BioTime Acquisition Corporation (BAC ...

View the full article

Quote

ImmInst 15 Nov 2012

Geron Announces Non-Binding Letter of Intent with BioTime Regarding Stem ...
Reuters - Nov 15, 2012

MENLO PARK, Calif., November 15, 2012 -- Geron Corporation (Nasdaq: GERN) today announced that the company has entered into a non-binding letter of intent (LOI) with BioTime, Inc. (NYSE: BTX) and BioTime's recently formed subsidiary, BioTime ...

View the full article

Quote

ImmInst 15 Nov 2012

BIOTIME, INC. : BioTime and BioTime Acquisition Corporation Announce ...
4-traders - Nov 15, 2012

BioTime, Inc. (NYSE MKT: BTX) and its recently formed subsidiary BioTime Acquisition Corporation (BAC) jointly announced today that they have entered into a non-binding letter of intent for a $10 million investment from a private investor to provide ...

View the full article

Quote

ImmInst 19 Nov 2012

LifeMap Sciences, a Subsidiary of BioTime, Announces Release of GeneCards ...
DailyFinance - 2 hours ago

(BUSINESS WIRE)-- LifeMap Sciences, Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX), announced today the release of GeneCards®, Version 3.09, on November 18, 2012.

View the full article

Quote

ImmInst 15 Nov 2012

BIOTIME, INC. : BioTime Announces Non-Binding Letter of Intent with Geron ...
4-traders - Nov 15, 2012

BioTime, Inc. (NYSE MKT: BTX) and its recently formed subsidiary BioTime Acquisition Corporation (BAC) jointly announced today that they have entered into a non-binding letter of intent (LOI) with Geron Corporation.

View the full article

Quote